A Mechanistic In Vivo/Ex Vivo Pharmacokinetic‐Pharmacodynamic Model of Tenofovir for HIV Prevention

A Mechanistic In Vivo/Ex Vivo Pharmacokinetic‐Pharmacodynamic Model of Tenofovir for HIV Prevention

Defining tissue and plasma‐specific prophylactic drug concentrations is central to pre‐exposure prophylaxis product development for sexual transmission of HIV‐1. Pharmacokinetic (PK) data from study RMP‐02/MTN‐006 comparing single dose oral tenofovir disoproxil fumarate with single and multiple dose...

Full description

Bibliographic Details
Main Authors:	Priya Jayachandran, Maria Garcia-Cremades, Katarina Vučićević, Namandjé N. Bumpus, Peter Anton, Craig Hendrix, Radojka Savić
Format:	Article
Language:	English
Published:	Wiley 2021-03-01
Series:	CPT: Pharmacometrics & Systems Pharmacology
Online Access:	https://doi.org/10.1002/psp4.12583

Similar Items

Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 study.
by: Nicola Richardson-Harman, et al.
Published: (2014-01-01)

The Pre-clinical Toolbox of Pharmacokinetics and Pharmacodynamics: in vitro and ex vivo Models
by: Carolina Herrera
Published: (2019-05-01)

Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner
by: Julie M. Lade, et al.
Published: (2015-09-01)

A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.
by: Kuo-Hsiung Yang, et al.
Published: (2014-01-01)

Pharmacokinetics and pharmacodynamics of protein turnover and production in vivo
by: Kim, Jonghan
Published: (2004)

In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide.
by: Lisa C Rohan, et al.
Published: (2010-02-01)

Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection.
by: Sulav Duwal, et al.
Published: (2012-01-01)

Correction: Pharmacokinetics and Pharmacodynamics of the Reverse Transcriptase Inhibitor Tenofovir and Prophylactic Efficacy against HIV-1 Infection
by: Sulav Duwal, et al.
Published: (2012-01-01)

Correction: Pharmacokinetics and Pharmacodynamics of the Reverse Transcriptase Inhibitor Tenofovir and Prophylactic Efficacy against HIV-1 Infection.
by: Sulav Duwal, et al.
Published: (2012-01-01)

Neuroprotective Effect of Ropinirole Lipid Nanoparticles Enriched Hydrogel for Parkinson’s Disease: In Vitro, Ex Vivo, Pharmacokinetic and Pharmacodynamic Evaluation
by: Narendar Dudhipala, et al.
Published: (2020-05-01)

Pharmacokinetics and pharmacodynamics of recombinant human EPO-Fc fusion protein in vivo.
by: Xunlong Shi, et al.
Published: (2013-01-01)

Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.
by: Andrea Ries Thurman, et al.
Published: (2018-01-01)

MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
by: Craig W Hendrix, et al.
Published: (2013-01-01)

Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics
by: Bianca Vora, et al.
Published: (2021-07-01)

In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens
by: Xia Xiao, et al.
Published: (2018-11-01)

A Novel Microspheres Formulation of Puerarin: Pharmacokinetics Study and In Vivo Pharmacodynamics Evaluations
by: Xiao Song, et al.
Published: (2016-01-01)

Pharmacokinetic/pharmacodynamic profiles of baicalin against Mycoplasma gallisepticum in an in vivo infection model
by: Jiaxin Bao, et al.
Published: (2021-11-01)

Pharmacokinetic characteristics, pharmacodynamic effect and in vivo antiviral efficacy of liver-targeted interferon alpha.
by: Daniel Rycroft, et al.
Published: (2015-01-01)

Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane/tazobactam: an ex vivo and in vivo study
by: Camille Mané, et al.
Published: (2020-05-01)

Pharmacokinetic and pharmacodynamic
by: 蔡東湖
Published: (1995)

Correction: Pharmacokinetic characteristics, pharmacodynamic effect and in vivo antiviral efficacy of liver-targeted interferon alpha.
by: PLOS ONE Staff
Published: (2015-01-01)

In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Danofloxacin in Rabbits Infected With Salmonella typhimurium After Oral Administration
by: Xia Xiao, et al.
Published: (2018-04-01)

In vivo and in silico characterization of apocynin in reducing organ oxidative stress: A pharmacokinetic and pharmacodynamic study
by: Fangfei Liu, et al.
Published: (2020-08-01)

Etodolac transdermal cubosomes for the treatment of rheumatoid arthritis: ex vivo permeation and in vivo pharmacokinetic studies
by: Salwa Salah, et al.
Published: (2017-01-01)

A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).
by: Ian Mcgowan, et al.
Published: (2015-01-01)

Curcumin-loaded colloidal carrier system: formulation optimization, mechanistic insight, ex vivo and in vivo evaluation
by: Naz Z, et al.
Published: (2015-07-01)

Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics
by: Nicolas Bertrand, et al.
Published: (2017-10-01)

Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics
by: Grenier, Philippe, et al.
Published: (2018)

In Vivo Pharmacokinetics/Pharmacodynamics of Cefquinome in an Experimental Mouse Model of Staphylococcus Aureus Mastitis following Intramammary Infusion.
by: Yang Yu, et al.
Published: (2016-01-01)

In vivo visualization of PARP inhibitor pharmacodynamics
by: Elizabeth S. McDonald, et al.
Published: (2021-04-01)

In Vivo Pharmacodynamic Imaging of Proteasome Inhibition
by: Erin A. Kimbrel, et al.
Published: (2009-05-01)

Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.
by: Andrea Ries Thurman, et al.
Published: (2019-01-01)

Linking the Population Pharmacokinetics of Tenofovir and Its Metabolites With Its Cellular Uptake and Metabolism
by: K Madrasi, et al.
Published: (2014-11-01)

Development of Level A In Vitro–Vivo Correlation for Electrosprayed Microspheres Containing Leuprolide: Physicochemical, Pharmacokinetic, and Pharmacodynamic Evaluation
by: Dong-Seok Lee, et al.
Published: (2020-01-01)

In vivo and in vitro studies of factors affecting etoposide pharmacokinetic and pharmacodynamic variabilities; the influence of protein binding and an active metabolite
by: Ghazaly Kerwash, Essam Ahmed
Published: (2008)

Biphasic Elimination of Tenofovir Diphosphate and Nonlinear Pharmacokinetics of Zidovudine Triphosphate in a Microdosing Study
by: Chen, Jianmeng, et al.
Published: (2014)

Pharmacokinetics and Ex-vivo Free Radical Scavenging Effectof Polyphenols in Folium Sennae
by: Min-Yu Chen, et al.
Published: (2009)

Urinary Pharmacokinetic and Pharmacodynamic Profiles of Fosfomycin against Extended-Spectrum β-Lactamase-Producing <i>Escherichia coli</i> with Canine Ex Vivo Modeling: A Pilot Study
by: Kazuki Harada, et al.
Published: (2020-05-01)

Population pharmacokinetics and pharmacodynamics of pyronaridine
by: Methaneethorn, Janthima
Published: (2013)

Pharmacokinetic and Pharmacodynamic Studies in Anesthetics
by: Wen-YingChou, et al.
Published: (2019)